To amend the Federal Food, Drug, and Cosmetic Act to provide for expedited approval of priority nonprescription drugs, and for other purposes.

This bill creates a new program to speed up the approval process for specific over-the-counter drugs that could offer significant public health benefits. Drug companies can request this "priority" status for new medications intended for conditions that currently require a prescription, provided the drugs are new or contain active ingredients never seen in nonprescription products. If approved, the FDA will assign senior staff and specialized teams to work closely with the companies, offering faster guidance and more efficient review schedules while maintaining the same safety and effectiveness standards. The program includes a requirement to publish a list of eligible health conditions and will expire in September 2032 unless renewed by Congress.